The federal Project Grant award R01CA292941, funded by the National Cancer Institute's Cancer Biology Research program (CFDA 93.396), will support research by The Children's Hospital Corporation, doing business as Boston Children's Hospital, to investigate the mechanisms underlying genetic predisposition to pediatric B-cell acute lymphoblastic leukemia (B-ALL). The $695,464 award, spanning 5 years from July 2024 to June 2029, will integrate results from a large multi-ancestry genome-wide association study (GWAS) with single-cell epigenomic data to pinpoint causal genetic variants and their impact on normal B-cell development. This innovative approach aims to uncover mechanistic insights into the root causes of B-ALL that could inform future preventive strategies. The research will focus on variant-to-function mapping for known B-ALL risk loci, generating new single-cell multi-omic data on B-cell differentiation, and using genome editing to investigate the functional impact of prioritized causal variants.
Generated 2/25/25, 2:52 AM